Francesca Cura

Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first-line ibrutinib: a nationwide registry study from the Italian Medicines Agency

A. Cuneo, P. Russo, S. Celant, 2023, Blood cancer journal.

COMPLEX KARYOTYPE IN UNFIT PATIENTS WITH CLL TREATED WITH IBRUTINIB AND RITUXIMAB. THE GIMEMA LLC1114 PHASE 2 STUDY.

R. Foà, S. Molica, M. Vignetti, 2021, Blood.